NDASUBCUTANEOUSSOLUTION
Approved
Jun 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Mechanism of Action
double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
Indications (6)
Clinical Trials (3)
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Started Dec 2024
700 enrolled
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Started Nov 2019
655 enrolled
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Started Feb 2019
164 enrolled
Amyloidosis, HereditaryTransthyretin Amyloidosis
Loss of Exclusivity
LOE Date
Jul 28, 2036
126 months away
Patent Expiry
Jul 28, 2036
Exclusivity Expiry
Jun 13, 2029